U.S. markets closed

Inventiva S.A. (IVA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
12.56-0.13 (-1.02%)
At close: 03:33PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Up

Gap Up

Previous Close12.69
Bid12.50 x 1400
Ask13.66 x 800
Day's Range12.50 - 12.80
52 Week Range10.52 - 17.90
Avg. Volume4,479
Market Cap519.003M
Beta (5Y Monthly)0.90
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for IVA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Inventiva S.A. - American Depos
    Daily – Vickers Top Insider Picks for 01/20/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Benzinga

    Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022

    Inventiva (NASDAQ: IVA) announced the design of Phase 2a combination trial of lanifibranor in patients with type 2 diabetes (T2D) and non-cirrhotic non-alcoholic steatohepatitis (NASH). The trial will assess lanifibranor combined with Eli Lilly And Co's (NYSE: LLY) Jardiance (empagliflozin). The trial's primary efficacy endpoint is a change in Hemoglobin A1c (HbA1c) at the end of the 24-week treatment compared to baseline. Secondary endpoints include changes in liver enzymes, glycaemic and lipid

  • Benzinga

    Fast Track Status Expanded For Inventiva's NASH Treatment

    The FDA has decided that the Fast Track designation previously granted to Inventiva SA's (NASDAQ: IVA) lanifibranor in NASH encompasses the treatment of NASH patients with compensated cirrhosis. The decision follows a Fast Track designation request for lanifibranor in NASH with compensated cirrhosis filed by Inventiva with the FDA in August. Previously, the agency granted both Fast Track and Breakthrough Therapy designations to lanifibranor for NASH treatment in September 2019 and October 2020,